Table II:

Univariate Analysis of Baseline Clinical and Treatment Outcomes and their Impact on PFS and OS after Frontline BR among the Entire Study Population (N = 640)

	PFS			OS
	HR (95% CI)	p		HR (95% CI)	p
LDH
Elevated/Normal Range	2.40 (1.64–3.26)	<0.001		2.47 (1.36–4.48)	0.003
Bone Marrow
Involved/Not-involved	1.50 (0.91–2.48)	0.11		1.43 (0.69–2.95)	0.33
Stage
III-IV/I-II	1.19 (0.64–2.20)	0.6		0.83 (0.36–1.96)	0.68
B Symptoms
Present/Absent	2.00 (1.30–3.10)	0.002		3.72 (2.00–6.93)	<0.001
B2-microglobulin
Elevated/Normal Range	1.78 (0.98–3.22)	0.06		3.30 (1.90–9.17)	0.02
Number of Nodal Sites
> 4/< 4	1.41 (0.98–2.02)	0.06		1.35 (0.76–2.32)	0.28
Haemoglobin
<120 g/l/ Normal	1.90 (1.28–2.82)	0.001		2.94 (1.66–5.18)	<0.001
FLIPI
High (3–5)/Low (0–2)	2.44 (1.64–3.61)	<0.001		3.48( 1.78–6.81)	<0.001
Grade
Grade IIIa/Grade I-II	1.61 (0.98–2.63)	0.06		2.34 (1.89–4.61)	0.01
Response
CR/PR	0.46 (0.29–0.73)	0.001		0.43 (0.19–0.94)	0.03
Treatment Arm
MR/No maintenance	0.39 (0.29–0.55)	<0.001		0.42 (0.25–0.69)	0.001

BR; bendamustine and rituximab; CI: confidence interval;CR: complete remission; FLIPI: Follicular lymphoma International Prognostic Index; HR: hazard ratio; LDH: lactate dehydrogenase; MR: maintenance rituximab; OS: overall survival; PFS: progression-free survival; PR: partial remission